Annals of Thoracic Medicine Official publication of the Saudi Thoracic Society, affiliated to King Saud University
Search Ahead of print Current Issue Archives Instructions Subscribe e-Alerts Login 
Home Email this article link Print this article Bookmark this page Decrease font size Default font size Increase font size
This article has been cited by
1The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
Donald L. Smith,Jaime Acquaviva,Manuel Sequeira,John-Paul Jimenez,Chaohua Zhang,Jim Sang,Richard C. Bates,David A. Proia
Targeted Oncology.2015;10(2)235
2FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
Álvaro Quintanal-Villalonga,Irene Ferrer,Elizabeth Guruceaga,Cristina Cirauqui,Ángela Marrugal,Laura Ojeda,Santiago García,Jon Zugazagoitia,Sandra Muñoz-Galván,Fernando Lopez-Rios,Luis Montuenga,Silvestre Vicent,Sonia Molina-Pinelo,Amancio Carnero,Luis Paz-Ares
324h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Florent Baty,Markus Joerger,Martin Früh,Dirk Klingbiel,Francesco Zappa,Martin Brutsche
Journal of Translational Medicine.2017;15(1)102683
424h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Giuseppe Tridente
Journal of Translational Medicine.2017;15(1)123
5The 4717C?>?G polymorphism in periplakin modulates sensitivity to EGFR inhibitors
Hui Mei Lee,Gregory Michael Kelly,Nur Syafinaz Zainal,Pei San Yee,Muhammad Zaki Hidayatullah Fadlullah,Bernard Kok Bang Lee,Chai Phei Gan,Vyomesh Patel,Sok Ching Cheong
Scientific Reports.2019;9(1)123
6Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
Hua Yang,Rong Wang,Shunli Peng,Longhua Chen,Qi Li,Wei Wang
7Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung
Glenwood D. Goss,Johanna N. Spaans
The Oncologist.2016;21(2)205
8Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM)
Zhi-Hong Xu,Cai-Hong Liu,Jun-Biao Hang,Bei-Li Gao,Jia-An Hu
Cancer Biomarkers.2017;20(4)581
9Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies
Peng Jiang,Winston Lee,Xujuan Li,Carl Johnson,Jun S. Liu,Myles Brown,Jon Christopher Aster,X. Shirley Liu
Cell Systems.2018;6(3)343
10Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents
Cristina Minnelli,Emiliano Laudadio,Giovanna Mobbili,Roberta Galeazzi
International Journal of Molecular Sciences.2020;21(5)1721
11S100A4 Is an Independent Prognostic Factor for Patients with Lung Cancer: A Meta-Analysis
Hao Bai,Jia-Lin Qian,Bao-Hui Han
Genetic Testing and Molecular Biomarkers.2014;18(5)371
12Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
Jeng-Sen Tseng,Chih-Liang Wang,Ming-Shyan Huang,Chung-Yu Chen,Cheng-Yu Chang,Tsung-Ying Yang,Chi-Ren Tsai,Kun-Chieh Chen,Kuo-Hsuan Hsu,Meen-Hsin Tsai,Sung-Liang Yu,Kang-Yi Su,Chih-Wei Wu,Cheng-Ta Yang,Yuh-Min Chen,Gee-Chen Chang,Jung Weon Lee
PLoS ONE.2014;9(9)e107160
13Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study
Wolfgang M. Brueckl,H. Jost Achenbach,Joachim H. Ficker,Wolfgang Schuette
BMC Cancer.2018;18(1)e107160
  About the journal 
  Editorial Board 
  Saudi Thoracic Society(STS)
  Most popular articles 
  My Preferences 

Submit Articles


Join us

Most pupular articles